609 related articles for article (PubMed ID: 24378873)
1. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
2. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.
Winbanks CE; Murphy KT; Bernardo BC; Qian H; Liu Y; Sepulveda PV; Beyer C; Hagg A; Thomson RE; Chen JL; Walton KL; Loveland KL; McMullen JR; Rodgers BD; Harrison CA; Lynch GS; Gregorevic P
Sci Transl Med; 2016 Jul; 8(348):348ra98. PubMed ID: 27440729
[TBL] [Abstract][Full Text] [Related]
3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
4. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
5. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
6. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
7. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
9. Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Matsuyama T; Ishikawa T; Okayama T; Oka K; Adachi S; Mizushima K; Kimura R; Okajima M; Sakai H; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Kokura S; Naito Y; Itoh Y
Int J Cancer; 2015 Dec; 137(11):2558-65. PubMed ID: 26016447
[TBL] [Abstract][Full Text] [Related]
10. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
11. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.
Chen JL; Walton KL; Hagg A; Colgan TD; Johnson K; Qian H; Gregorevic P; Harrison CA
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5266-E5275. PubMed ID: 28607086
[TBL] [Abstract][Full Text] [Related]
12. A non-human primate model of radiation-induced cachexia.
Cui W; Bennett AW; Zhang P; Barrow KR; Kearney SR; Hankey KG; Taylor-Howell C; Gibbs AM; Smith CP; MacVittie TJ
Sci Rep; 2016 Mar; 6():23612. PubMed ID: 27029502
[TBL] [Abstract][Full Text] [Related]
13. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Samant SA; Kanwal A; Pillai VB; Bao R; Gupta MP
Sci Rep; 2017 Sep; 7(1):11877. PubMed ID: 28928419
[TBL] [Abstract][Full Text] [Related]
15. Activin A induces skeletal muscle catabolism via p38β mitogen-activated protein kinase.
Ding H; Zhang G; Sin KW; Liu Z; Lin RK; Li M; Li YP
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):202-212. PubMed ID: 27897407
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
17. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3β Signaling Pathway.
Shen C; Zhou J; Wang X; Yu XY; Liang C; Liu B; Pan X; Zhao Q; Song JL; Wang J; Bao M; Wu C; Li Y; Song YH
EBioMedicine; 2017 Feb; 16():238-250. PubMed ID: 28161398
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
20. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Lee SJ; Lehar A; Meir JU; Koch C; Morgan A; Warren LE; Rydzik R; Youngstrom DW; Chandok H; George J; Gogain J; Michaud M; Stoklasek TA; Liu Y; Germain-Lee EL
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23942-23951. PubMed ID: 32900939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]